Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
our-team
practice-areas
investment-products

Investigations

Melissa Fry Hague, Esq. Joins Goldman Scarlato & Penny, P.C.

Goldman Scarlato & Penny, P.C. is pleased to announce that Melissa Fry Hague, Esquire has joined the firm as a partner. Melissa will lead the firm’s new Mass Tort litigation practice, and brings over ten years’ experience litigating cases involving dangerous drugs and defective medical devices. She currently serves on the Plaintiffs’ Steering Committee in In Re: Zofran (Ondansetron) Products Liability Litigation, and has successfully represented hundreds of plaintiffs injured by defective metal-on-metal hip implants, and knee implants. Melissa has also successfully represented victims who received infected and stolen cadaver bone in the In re: Human Tissue Products Liability Litigation, and has been a fierce advocate for women harmed by defective transvaginal mesh products and Fosamax. Melissa has earned a reputation as a diligent and zealous attorney among her peers, both locally and nationally.

Melissa’s passion for justice extends to her active involvement in the American Association for Justice where she currently serves as the Chair of the New Lawyers Division. Melissa earned her J.D. from Widener University School of Law in 2006, and is admitted to practice in Pennsylvania and New Jersey. Prior to joining Goldman Scarlato & Penny, P.C. Melissa was a partner at a premiere personal injury firm in Philadelphia.

In our legal system, every person is innocent until and unless found guilty by a court of law or a tribunal. Whenever we reference “allegations” or charges that are “alleged,” such allegations or charges have not been proven, and are merely accusations, not findings of fault, as of the date of the blog. We do not have, nor do we undertake, a duty to continue to monitor or follow cases about which we report, and/or to publish subsequent updates regarding various developments that may occur in such cases. Readers are encouraged to conduct their own research regarding any such cases and any developments that may or may not have occurred in such cases. Also, the brokercheck report linked to some of our blogs is the up-to-date version as of the date of posting. Visitors may check the most recent version of each brokercheck report at www.finra.org.

Leave a Reply